114 studies found for:    Open Studies | "Peritoneal Diseases"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Peritoneal Diseases"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
Conditions: Spontaneous Bacterial Peritonitis;   Ascites;   Liver Cirrhosis
Interventions: Drug: Rifaximin;   Drug: Norfloxacin
2 Recruiting Functional Genomic Influences on Disease Progression and Outcome in Sepsis
Conditions: Pneumonia;   Peritonitis
Intervention:
3 Recruiting Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hepatic and Renal Dysfunction After Pneumoperitoneum
Conditions: Hepatic Dysfunction Transient;   Renal Function Disorder
Interventions: Other: TEAS pretreatment;   Other: TEAS treatment
4 Unknown  Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal
Conditions: Portal Hypertension Gastropathy;   Esophageal Varices;   Spontaneous Bacterial Peritonitis;   Hepatic Encephalopathy;   Ascites
Interventions: Drug: propranolol;   Drug: carvedilol;   Drug: placebo
5 Recruiting Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
Conditions: Relapsed Epithelial Ovarian Cancer;   Relapsed Primary Peritoneal Cancer;   Relapsed Fallopian Tube Cancer
Interventions: Drug: Birinapant;   Drug: Conatumumab
6 Unknown  Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: liposome-encapsulated doxorubicin citrate;   Procedure: quality-of-life assessment
7 Recruiting Quality of Life Questionnaire for Pediatric Patients Undergoing Peritoneal Perfusion
Condition: Peritoneal Neoplasms
Intervention: Behavioral: Questionnaire
8 Unknown  Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Drug: docetaxel;   Drug: idronoxil;   Other: placebo
9 Recruiting An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA)
Condition: Peritoneal Neoplasms
Intervention:
10 Recruiting Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis
Conditions: Malignant Neoplasm of Stomach;   Secondary Malignant Neoplasm of Peritoneum;   Secondary Malignant Neoplasm of Other and Unspecified Sites
Intervention: Procedure: HIPEC
11 Recruiting Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Conditions: Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: letrozole;   Drug: tamoxifen citrate;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: topotecan hydrochloride;   Drug: trametinib;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: pharmacological study
12 Recruiting Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
Conditions: Cirrhosis;   Ascites;   Nosocomial Spontaneous Bacterial Peritonitis
Interventions: Drug: Daptomycin + Meropenem;   Drug: Ceftazidime
13 Recruiting HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry
Conditions: Peritoneal Neoplasms;   Neoplasm Metastasis;   Adenocarcinoma;   Sarcoma
Intervention:
14 Not yet recruiting Adjuvant HIPEC in High Risk Colon Cancer
Conditions: Colorectal Neoplasms;   Peritoneal Neoplasms
Interventions: Procedure: Adjuvant HIPEC (open/laparoscopic);   Drug: Standard adjuvant systemic chemotherapy;   Procedure: Diagnostic laparoscopy
15 Recruiting Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: NK cells;   Biological: IL-2;   Drug: INCB024360
16 Unknown  The Study of Infection and Cell Inflammation in Peritoneal Dialysate
Conditions: Peritonitis;   Kidney Failure
Intervention:
17 Recruiting A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Conditions: Urinary Bladder Neoplasms;   Carcinoma, Transitional Cell;   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Pancreatic Ductal;   Tumor Virus Infections
Interventions: Drug: CC-486 plus Carboplatin;   Drug: CC-486 plus ABI-007;   Drug: CC-486
18 Recruiting Laparoscopic Peritoneal Lavage or Resection for Generalised Peritonitis for Perforated Diverticulitis
Condition: Perforated Diverticulitis
Interventions: Procedure: Laparoscopic lavage and drainage;   Procedure: Sigmoidectomy with primary anastomosis;   Procedure: Sigmoidectomy with end-colostomy
19 Not yet recruiting Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Brenner Tumor;   Malignant Ascites;   Malignant Pleural Effusion;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: docetaxel;   Drug: metformin hydrochloride;   Drug: placebo;   Other: laboratory biomarker analysis
20 Recruiting Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Papillary Serous Carcinoma;   Ovarian Serous Cystadenocarcinoma;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Triple-negative Breast Cancer
Interventions: Drug: olaparib;   Drug: cediranib maleate;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years